(9/21), and 38.1 (8/21) of the patients in the INT Group continued to perceive improvements compared with 13.0 (3/23), 13.0 (3/23) and 8.7 (2/23) in the WL Group (Fig 4) (one subject in the INT Group returned the questionnaire at T2 but not at T1). As previously mentioned, additional PGIC ratings were collected in the WL Group (17/23) at the end of the trial once they also completed the PASSAGE Program. Close to 60 of them reported improvements in their pain (58.8 ; 10/17), functioning (58.8 ; 10/17), and QOL (58.8 ; 10/17) between T0 and T1, while the percentage of those who continued to improve on these indicators 3 STI-571 web months following the intervention was 35.29 (6/17), 23.53 (4/17), and 29.41 (5/17) respectively.PLOS ONE | DOI:10.1371/journal.pone.0126324 May 15,14 /Multicomponent Group Intervention for Self-Management of FibromyalgiaTable 3. Magnitude and significance of the improvements in the intervention (INT, n = 28) and the waitlist (WL, n = 29) groups up to three months post-intervention. Baseline (T0) End of the intervention (T1) 3 months post-intervention (T2) Repeated measures analyses p-values** Group x Time effectStudy outcomes*INT GroupWL GroupINT GroupWL GroupEffect sizeand 95 CIINT GroupWL GroupEffect size and 95 CIPRIMARY OUTCOME Pain intensity Pain on the average in the past 7 days (NRS: 0?0) SECONDARY OUTCOMES Severity of FMS Total FIQ score (0?00) Pain interference BPI interference mean score (0?10) Sleep quality CPSI–Overall sleep quality item (0?0) CPSI–Sleep Problem Index score (0?0) Coping Strategy Questionnaire Ignoring Pain Sensations SP600125 solubility Subscale (0?5) Diverting Attention Subscale (0?5) Catastrophizing Subscale (0?2) Reinterpreting Pain Sensations Subscale (0?2) Praying Subscale (0?) Pain catastrophizing Total PCS score (0?2) Depression levels (Continued) 23.54 ?11.10 22.04 ?11.98 17.86 ?9.83 18.88 ?12.75 -1.02 (-7.78?5.74) 15.62 ?13.43 20.00 ?11.23 -4.38 (-11.97?3.21) 0.193, 0.234, 0.364 7.14 ?3.14 ?3.82 ?3.00 ?3.06 ?2.04 5.93 ?2.61 ?2.59 ?3.05 ?2.26 ?2.67 6.41 ?2.28 ?2.65 ?2.61 ?3.49 ?2.27 6.52 ?2.60 ?2.06 ?3.13 ?2.17 ?2.78 -0.11 (-1.56?1.34) -0.59 (-1.98?0.80) 0.22 (-1.49?1.93) 0.60 (-1.09?2.29) -0.83 (-2.33?0.67) 8.10 ?3.13 ?3.21 ?2.91 ?3.75 ?2.42 6.00 ?2.65 ?2.37 ?2.88 ?2.85 ?2.98 2.10 (0.32?3.88) 0.62 (-1.10?2.34) -0.75 (-2.54?1.04) 1.40 (-0.64?3.44) -0.73 (-2.42?0.96) 0.010, 0.014, 0.052 0.121, 0.118, 0.219 0.496, 0.532, 0.724 0.961, 0.972, 0.969 0.789, 0.785, 0.820 2.75 ?1.82 ?8.49 2.89 ?2.59 ?7.91 4.09 ?2.04 ?7.41 3.72 ?2.30 ?7.72 0.37 (-0.92?1.66) -2.62 (-7.08?1.84) 4.33 ?2.18 ?8.60 3.57 ?2.37 ?8.00 0.76 (-0.65?2.17) -2.46 (-7.57?2.65) 0.512, 0.578, 0.691 0.711, 0.732, 0.877 5.09 ?2.38 5.36 ?2.40 4.63 ?2.15 4.99 ?2.32 -0.36 (-1.68?0.96) 4.08 ?2.14 4.72 ?2.24 -0.64 (-1.99?0.71) 0.954, 0.958, 0.988 64.68 ?16.80 62.43 ?18.90 55.11 ?16.22 56.68 ?20.66 -1.57 (-12.59?9.45) 51.49 ?16.27 55.18 ?20.44 -3.69 (-15.19?7.18) 0.465, 0.537, 0.665 6.57 ?2.03 6.39 ?1.83 5.95 ?2.06 6.08 ?2.14 -0.13 (-1.37?1.11) 5.36 ?1.74 5.91 ?2.29 -0.55 (-1.82?0.72) 0.669, 0.701, 0.18.18.12.15.14.16.7.7.7.8.7.7.4.4.3.3.3.4.3.2.3.2.4.2.2.3.2.2.2.2.PLOS ONE | DOI:10.1371/journal.pone.0126324 May 15,15 /Multicomponent Group Intervention for Self-Management of FibromyalgiaTable 3. (Continued) Baseline (T0) End of the intervention (T1) 3 months post-intervention (T2) Repeated measures analyses p-values** Group x Time effectStudy outcomes*INT GroupWL GroupINT GroupWL GroupEffect sizeand 95 CI 0.35 (-5.12?5.82)INT GroupWL GroupEffe.(9/21), and 38.1 (8/21) of the patients in the INT Group continued to perceive improvements compared with 13.0 (3/23), 13.0 (3/23) and 8.7 (2/23) in the WL Group (Fig 4) (one subject in the INT Group returned the questionnaire at T2 but not at T1). As previously mentioned, additional PGIC ratings were collected in the WL Group (17/23) at the end of the trial once they also completed the PASSAGE Program. Close to 60 of them reported improvements in their pain (58.8 ; 10/17), functioning (58.8 ; 10/17), and QOL (58.8 ; 10/17) between T0 and T1, while the percentage of those who continued to improve on these indicators 3 months following the intervention was 35.29 (6/17), 23.53 (4/17), and 29.41 (5/17) respectively.PLOS ONE | DOI:10.1371/journal.pone.0126324 May 15,14 /Multicomponent Group Intervention for Self-Management of FibromyalgiaTable 3. Magnitude and significance of the improvements in the intervention (INT, n = 28) and the waitlist (WL, n = 29) groups up to three months post-intervention. Baseline (T0) End of the intervention (T1) 3 months post-intervention (T2) Repeated measures analyses p-values** Group x Time effectStudy outcomes*INT GroupWL GroupINT GroupWL GroupEffect sizeand 95 CIINT GroupWL GroupEffect size and 95 CIPRIMARY OUTCOME Pain intensity Pain on the average in the past 7 days (NRS: 0?0) SECONDARY OUTCOMES Severity of FMS Total FIQ score (0?00) Pain interference BPI interference mean score (0?10) Sleep quality CPSI–Overall sleep quality item (0?0) CPSI–Sleep Problem Index score (0?0) Coping Strategy Questionnaire Ignoring Pain Sensations Subscale (0?5) Diverting Attention Subscale (0?5) Catastrophizing Subscale (0?2) Reinterpreting Pain Sensations Subscale (0?2) Praying Subscale (0?) Pain catastrophizing Total PCS score (0?2) Depression levels (Continued) 23.54 ?11.10 22.04 ?11.98 17.86 ?9.83 18.88 ?12.75 -1.02 (-7.78?5.74) 15.62 ?13.43 20.00 ?11.23 -4.38 (-11.97?3.21) 0.193, 0.234, 0.364 7.14 ?3.14 ?3.82 ?3.00 ?3.06 ?2.04 5.93 ?2.61 ?2.59 ?3.05 ?2.26 ?2.67 6.41 ?2.28 ?2.65 ?2.61 ?3.49 ?2.27 6.52 ?2.60 ?2.06 ?3.13 ?2.17 ?2.78 -0.11 (-1.56?1.34) -0.59 (-1.98?0.80) 0.22 (-1.49?1.93) 0.60 (-1.09?2.29) -0.83 (-2.33?0.67) 8.10 ?3.13 ?3.21 ?2.91 ?3.75 ?2.42 6.00 ?2.65 ?2.37 ?2.88 ?2.85 ?2.98 2.10 (0.32?3.88) 0.62 (-1.10?2.34) -0.75 (-2.54?1.04) 1.40 (-0.64?3.44) -0.73 (-2.42?0.96) 0.010, 0.014, 0.052 0.121, 0.118, 0.219 0.496, 0.532, 0.724 0.961, 0.972, 0.969 0.789, 0.785, 0.820 2.75 ?1.82 ?8.49 2.89 ?2.59 ?7.91 4.09 ?2.04 ?7.41 3.72 ?2.30 ?7.72 0.37 (-0.92?1.66) -2.62 (-7.08?1.84) 4.33 ?2.18 ?8.60 3.57 ?2.37 ?8.00 0.76 (-0.65?2.17) -2.46 (-7.57?2.65) 0.512, 0.578, 0.691 0.711, 0.732, 0.877 5.09 ?2.38 5.36 ?2.40 4.63 ?2.15 4.99 ?2.32 -0.36 (-1.68?0.96) 4.08 ?2.14 4.72 ?2.24 -0.64 (-1.99?0.71) 0.954, 0.958, 0.988 64.68 ?16.80 62.43 ?18.90 55.11 ?16.22 56.68 ?20.66 -1.57 (-12.59?9.45) 51.49 ?16.27 55.18 ?20.44 -3.69 (-15.19?7.18) 0.465, 0.537, 0.665 6.57 ?2.03 6.39 ?1.83 5.95 ?2.06 6.08 ?2.14 -0.13 (-1.37?1.11) 5.36 ?1.74 5.91 ?2.29 -0.55 (-1.82?0.72) 0.669, 0.701, 0.18.18.12.15.14.16.7.7.7.8.7.7.4.4.3.3.3.4.3.2.3.2.4.2.2.3.2.2.2.2.PLOS ONE | DOI:10.1371/journal.pone.0126324 May 15,15 /Multicomponent Group Intervention for Self-Management of FibromyalgiaTable 3. (Continued) Baseline (T0) End of the intervention (T1) 3 months post-intervention (T2) Repeated measures analyses p-values** Group x Time effectStudy outcomes*INT GroupWL GroupINT GroupWL GroupEffect sizeand 95 CI 0.35 (-5.12?5.82)INT GroupWL GroupEffe.
bet-bromodomain.com
BET Bromodomain Inhibitor
